A Retrospective Comparison of the Effectiveness of Buprenorphine Versus Baclofen for Acute Opioid Withdrawal

Overview

Journal HCA Healthc J Med

Specialty Health Services

Date 2023 Jul 10

PMID 37424975

Authors

Matthew Hermenau

Benton Stamper

Kitty Leung

Raymond Pomm

Christina Guerrier

Joseph Cammilleri

Brittany Johnson

Affiliations

Soon will be listed here.

Abstract

Background: A significant impediment to opioid cessation or dose reduction is mitigating withdrawal severity that has been shown to affect the course of opioid dependence. Current guidelines recommend the use of buprenorphine and methadone over alpha-2 adrenergic agonists. Baclofen, a GABA-B agonist, has promising results as an adjunct agent for opioid withdrawal but has not been compared to buprenorphine. This study compared the ability of buprenorphine and baclofen to mitigate acute opioid withdrawal.

Methods: This was a single-center, retrospective chart review of 63 patients with diagnosed opioid use disorder that received scheduled buprenorphine or baclofen for 3 days, in addition to as-needed medications during 2 distinct time periods (pre-2017 and 2017-2020). Patients were admitted to the inpatient detoxification unit at Gateway Community Services in Jacksonville, FL.

Results: The results showed that patients achieving detoxification success were 11.2 times more likely to be exposed to baclofen than buprenorphine (95% CI 3.32 - 37.83, < .001). Completion of detoxification protocol (baclofen 63.2% vs buprenorphine 72%, = .649) and incidence of orthostatic hypotension (15.8% versus 0%, = .073) were not significantly different between the 2 groups.

Conclusion: Patients treated with baclofen had a lower frequency of secondary medication use for acute opioid withdrawal than patients treated with buprenorphine. This raises an interesting question of whether baclofen is comparable to buprenorphine for treating opioid withdrawal. A prospective, randomized, controlled trial in a larger patient population is warranted to determine this difference.

Citing Articles

Ingestion of Fluids of the Ocular Surface Containing Eye Drops of Imidazole Derivatives-Alpha Adrenergic Receptor Agonists as Paragons.

Sosa I Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931425 PMC: 11206365. DOI: 10.3390/ph17060758.

References

Wesson D, Ling W . The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003; 35(2):253-9. DOI: 10.1080/02791072.2003.10400007. View

Xi Z, Stein E . Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. J Pharmacol Exp Ther. 1999; 290(3):1369-74. View

Raistrick D, West D, Finnegan O, Thistlethwaite G, Brearley R, Banbery J . A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial. Addiction. 2005; 100(12):1860-7. DOI: 10.1111/j.1360-0443.2005.01273.x. View

Ziaaddini H, Nasirian M, Nakhaee N . Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents. Addict Health. 2014; 4(3-4):79-86. PMC: 3905537. View

Fattore L, Cossu G, Martellotta M, Fratta W . Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol. 2002; 37(5):495-8. DOI: 10.1093/alcalc/37.5.495. View

Weiss R, Potter J, Griffin M, McHugh R, Haller D, Jacobs P . Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J Subst Abuse Treat. 2014; 47(2):140-5. PMC: 4074437. DOI: 10.1016/j.jsat.2014.03.004. View

Ranaldi R, Poeggel K . Baclofen decreases methamphetamine self-administration in rats. Neuroreport. 2002; 13(9):1107-10. DOI: 10.1097/00001756-200207020-00007. View

Trescot A, Datta S, Lee M, Hansen H . Opioid pharmacology. Pain Physician. 2008; 11(2 Suppl):S133-53. View

Umbricht A, Hoover D, Tucker M, Leslie J, Chaisson R, Preston K . Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend. 2003; 69(3):263-72. DOI: 10.1016/s0376-8716(02)00325-3. View

10.

Carlson R, Daniulaityte R, Silverstein S, Nahhas R, Martins S . Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?. Int J Drug Policy. 2020; 79:102722. PMC: 9387534. DOI: 10.1016/j.drugpo.2020.102722. View

11.

Lacey M, Mercuri N, North R . On the potassium conductance increase activated by GABAB and dopamine D2 receptors in rat substantia nigra neurones. J Physiol. 1988; 401:437-53. PMC: 1191858. DOI: 10.1113/jphysiol.1988.sp017171. View

12.

Ahmadi-Abhari S, Akhondzadeh S, Assadi S, Shabestari O, Farzanehgan Z, Kamlipour A . Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial. J Clin Pharm Ther. 2001; 26(1):67-71. DOI: 10.1046/j.1365-2710.2001.00325.x. View

13.

Florence C, Zhou C, Luo F, Xu L . The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016; 54(10):901-6. PMC: 5975355. DOI: 10.1097/MLR.0000000000000625. View

14.

Akhondzadeh S, Ahmadi-Abhari S, Assadi S, Shabestari O, Kashani A, Farzanehgan Z . Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. J Clin Pharm Ther. 2000; 25(5):347-53. DOI: 10.1046/j.1365-2710.2000.00295.x. View

15.

Shaw B, Borrel D, Sabbaghan K, Kum C, Yang Y, Robinovitch S . Relationships between orthostatic hypotension, frailty, falling and mortality in elderly care home residents. BMC Geriatr. 2019; 19(1):80. PMC: 6415493. DOI: 10.1186/s12877-019-1082-6. View

16.

Lintzeris N, Bell J, Bammer G, Jolley D, Rushworth L . A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction. 2002; 97(11):1395-404. DOI: 10.1046/j.1360-0443.2002.00215.x. View

17.

Nielsen S, Hillhouse M, Weiss R, Mooney L, Potter J, Lee J . The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. Am J Addict. 2013; 23(4):343-8. PMC: 4151625. DOI: 10.1111/j.1521-0391.2013.12105.x. View

18.

Sordo L, Barrio G, Bravo M, Indave B, Degenhardt L, Wiessing L . Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017; 357:j1550. PMC: 5421454. DOI: 10.1136/bmj.j1550. View

19.

Larochelle M, Bernson D, Land T, Stopka T, Wang N, Xuan Z . Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018; 169(3):137-145. PMC: 6387681. DOI: 10.7326/M17-3107. View

20.

Amato L, Davoli M, Minozzi S, Ali R, Ferri M . Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2005; (3):CD003409. DOI: 10.1002/14651858.CD003409.pub3. View